Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of Rujiexiao granules for mammary gland hyperplasia
CTR20210750Phase 2Active
- Sponsor
- Henan Taloph Pharmaceutical
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Rujiexiao in breast hyperplasia (4 arms), sponsored by Henan Taloph Pharmaceutical. Primary endpoints: Breast pain score, Pain duration and 1 more. Started Jun 2021; status: active.
02
Drugs
Rujiexiao
03
Conditions
breast hyperplasia
Beyond the preview
Go deeper on CTR20210750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210750.